Discuss Abbott Laboratories
Abbott Laboratories
WKN: 850103 / Symbol: ABT / Name: Abbott / Aktie / Pharmazeutika / Large Cap /
99,29 €
-0,90 %
Buy Abbott Laboratories
Buy Abbott Laboratories
Buy Abbott Laboratories
Buy Abbott Laboratories
Buy Abbott Laboratories
Buy Abbott Laboratories
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $140.00 to $136.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at UBS Group AG from $117.00 to $130.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wolfe Research from $107.00 to $103.00. They now have an "underperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Sanford C. Bernstein from $132.00 to $133.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at JPMorgan Chase & Co. from $118.00 to $122.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Raymond James from $123.00 to $110.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $136.00 to $116.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Wells Fargo & Company from $116.00 to $121.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Raymond James from $110.00 to $124.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Royal Bank of Canada from $119.00 to $128.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Raymond James from $124.00 to $127.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $128.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Citigroup Inc. from $123.00 to $126.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Barclays PLC from $133.00 to $141.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Neueste Beiträge
Loop_Capital in Crown Holdings Inc. diskutieren